Overcoming Adherence Challenges in Neovascular AMD

This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review challenges with standard-of-care treatments for neovascular age-related macular degeneration (nAMD), particularly the need for frequent injections, and the use of variable dosing strategies to address these challenges. The session will also review the safety and efficacy of newer strategies to improve treatment duration and patient adherence, including longer-acting drugs, longer-acting technologies, and gene therapies.

Upon completion of the educational activity, participants should be able to:

• Describe the best approaches to the treatment selection and ongoing management of nAMD
• Discuss the latest clinical research in nAMD, including the impact of recent trials and emerging therapies on patient care
• Implement the latest methods and data into clinical practice for the improved care of patients with nAMD

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com